The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ovarian Cancer Targeted Therapy Drugs Market Research Report 2025
Synopsis
Ovarian cancer is the most common cause of mortality for women with gynecological cancers Additionally, it ranks as the seventh most common cause of mortality for females overall. The majority of instances are discovered when the disease has already progressed, which leads to poor outcomes. The cancer cells can be marked with a specific targeted therapy, making it simpler for the immune system to recognize and eliminate them. In addition, some targeted therapies can help in enhancing the immune system so that it fights cancer effectively which further boost the market growth.
The global Ovarian Cancer Targeted Therapy Drugs market was valued at US$ 1669 million in 2023 and is anticipated to reach US$ 2991 million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
Asia-Pacific expected to grow at the highest rate during the ovarian cancer drugs market forecast. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in personalized medicine expenditure and adoption of high-tech processing to improve the production of ovarian cancer drugs, drive the growth of the market. In addition, high population base, presence of unmet medical needs, and increase in disposable incomes of people in the region further boost the market growth. Moreover, rise in medical tourism and developing healthcare infrastructure make Asia-Pacific a lucrative market for ovarian cancer drugs.Furthermore, increase in technological innovations in drug discovery, surge in funding provided by the government and private organizations, presence of large number of healthcare reforms, and increase in aging population of woman drive the growth of the market. Moreover, increase in demand for advanced healthcare services in emerging economies such as India and China are the major factors that drive the growth of the Asia-Pacific market. Asia-Pacific offers profitable opportunities for key players operating in the ovarian cancer drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
This report aims to provide a comprehensive presentation of the global market for Ovarian Cancer Targeted Therapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ovarian Cancer Targeted Therapy Drugs.
The Ovarian Cancer Targeted Therapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ovarian Cancer Targeted Therapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ovarian Cancer Targeted Therapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck KGaA
GlaxoSmithKline plc
Johnson & Johnson Services, Inc
F. Hoffmann-La Roche AG
Boehringer Ingelheim International GmbH
Abbvie Inc
AstraZeneca
Pfizer, Inc
Clovis Oncology
Amgen Inc.
Segment by Type
PARP Inhibitors
Angiogenesis Inhibitors
Others
Segment by Application
Hospital Pharmacy
Drug Stores and Retail Pharmacy
Online Providers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ovarian Cancer Targeted Therapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Ovarian cancer is the most common cause of mortality for women with gynecological cancers Additionally, it ranks as the seventh most common cause of mortality for females overall. The majority of instances are discovered when the disease has already progressed, which leads to poor outcomes. The cancer cells can be marked with a specific targeted therapy, making it simpler for the immune system to recognize and eliminate them. In addition, some targeted therapies can help in enhancing the immune system so that it fights cancer effectively which further boost the market growth.
The global Ovarian Cancer Targeted Therapy Drugs market was valued at US$ 1669 million in 2023 and is anticipated to reach US$ 2991 million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
Asia-Pacific expected to grow at the highest rate during the ovarian cancer drugs market forecast. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in personalized medicine expenditure and adoption of high-tech processing to improve the production of ovarian cancer drugs, drive the growth of the market. In addition, high population base, presence of unmet medical needs, and increase in disposable incomes of people in the region further boost the market growth. Moreover, rise in medical tourism and developing healthcare infrastructure make Asia-Pacific a lucrative market for ovarian cancer drugs.Furthermore, increase in technological innovations in drug discovery, surge in funding provided by the government and private organizations, presence of large number of healthcare reforms, and increase in aging population of woman drive the growth of the market. Moreover, increase in demand for advanced healthcare services in emerging economies such as India and China are the major factors that drive the growth of the Asia-Pacific market. Asia-Pacific offers profitable opportunities for key players operating in the ovarian cancer drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
This report aims to provide a comprehensive presentation of the global market for Ovarian Cancer Targeted Therapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ovarian Cancer Targeted Therapy Drugs.
The Ovarian Cancer Targeted Therapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ovarian Cancer Targeted Therapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ovarian Cancer Targeted Therapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck KGaA
GlaxoSmithKline plc
Johnson & Johnson Services, Inc
F. Hoffmann-La Roche AG
Boehringer Ingelheim International GmbH
Abbvie Inc
AstraZeneca
Pfizer, Inc
Clovis Oncology
Amgen Inc.
Segment by Type
PARP Inhibitors
Angiogenesis Inhibitors
Others
Segment by Application
Hospital Pharmacy
Drug Stores and Retail Pharmacy
Online Providers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ovarian Cancer Targeted Therapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PARP Inhibitors
1.2.3 Angiogenesis Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Ovarian Cancer Targeted Therapy Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Drug Stores and Retail Pharmacy
1.3.4 Online Providers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ovarian Cancer Targeted Therapy Drugs Market Perspective (2019-2030)
2.2 Global Ovarian Cancer Targeted Therapy Drugs Growth Trends by Region
2.2.1 Global Ovarian Cancer Targeted Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ovarian Cancer Targeted Therapy Drugs Historic Market Size by Region (2019-2024)
2.2.3 Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Region (2025-2030)
2.3 Ovarian Cancer Targeted Therapy Drugs Market Dynamics
2.3.1 Ovarian Cancer Targeted Therapy Drugs Industry Trends
2.3.2 Ovarian Cancer Targeted Therapy Drugs Market Drivers
2.3.3 Ovarian Cancer Targeted Therapy Drugs Market Challenges
2.3.4 Ovarian Cancer Targeted Therapy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ovarian Cancer Targeted Therapy Drugs Players by Revenue
3.1.1 Global Top Ovarian Cancer Targeted Therapy Drugs Players by Revenue (2019-2024)
3.1.2 Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Ovarian Cancer Targeted Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Ovarian Cancer Targeted Therapy Drugs Revenue
3.4 Global Ovarian Cancer Targeted Therapy Drugs Market Concentration Ratio
3.4.1 Global Ovarian Cancer Targeted Therapy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ovarian Cancer Targeted Therapy Drugs Revenue in 2023
3.5 Global Key Players of Ovarian Cancer Targeted Therapy Drugs Head office and Area Served
3.6 Global Key Players of Ovarian Cancer Targeted Therapy Drugs, Product and Application
3.7 Global Key Players of Ovarian Cancer Targeted Therapy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Ovarian Cancer Targeted Therapy Drugs Breakdown Data by Type
4.1 Global Ovarian Cancer Targeted Therapy Drugs Historic Market Size by Type (2019-2024)
4.2 Global Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Type (2025-2030)
5 Ovarian Cancer Targeted Therapy Drugs Breakdown Data by Application
5.1 Global Ovarian Cancer Targeted Therapy Drugs Historic Market Size by Application (2019-2024)
5.2 Global Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ovarian Cancer Targeted Therapy Drugs Market Size (2019-2030)
6.2 North America Ovarian Cancer Targeted Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024)
6.4 North America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ovarian Cancer Targeted Therapy Drugs Market Size (2019-2030)
7.2 Europe Ovarian Cancer Targeted Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024)
7.4 Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size (2019-2030)
8.2 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ovarian Cancer Targeted Therapy Drugs Market Size (2019-2030)
9.2 Latin America Ovarian Cancer Targeted Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024)
9.4 Latin America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size (2019-2030)
10.2 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck KGaA
11.1.1 Merck KGaA Company Details
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Introduction
11.1.4 Merck KGaA Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.1.5 Merck KGaA Recent Development
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Details
11.2.2 GlaxoSmithKline plc Business Overview
11.2.3 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Introduction
11.2.4 GlaxoSmithKline plc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.2.5 GlaxoSmithKline plc Recent Development
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Details
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Introduction
11.3.4 Johnson & Johnson Services, Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.3.5 Johnson & Johnson Services, Inc Recent Development
11.4 F. Hoffmann-La Roche AG
11.4.1 F. Hoffmann-La Roche AG Company Details
11.4.2 F. Hoffmann-La Roche AG Business Overview
11.4.3 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Introduction
11.4.4 F. Hoffmann-La Roche AG Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.4.5 F. Hoffmann-La Roche AG Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Details
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Abbvie Inc
11.6.1 Abbvie Inc Company Details
11.6.2 Abbvie Inc Business Overview
11.6.3 Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Introduction
11.6.4 Abbvie Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.6.5 Abbvie Inc Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Ovarian Cancer Targeted Therapy Drugs Introduction
11.7.4 AstraZeneca Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer, Inc
11.8.1 Pfizer, Inc Company Details
11.8.2 Pfizer, Inc Business Overview
11.8.3 Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Introduction
11.8.4 Pfizer, Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.8.5 Pfizer, Inc Recent Development
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Details
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Introduction
11.9.4 Clovis Oncology Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.9.5 Clovis Oncology Recent Development
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Details
11.10.2 Amgen Inc. Business Overview
11.10.3 Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Introduction
11.10.4 Amgen Inc. Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
11.10.5 Amgen Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of PARP Inhibitors
Table 3. Key Players of Angiogenesis Inhibitors
Table 4. Key Players of Others
Table 5. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Ovarian Cancer Targeted Therapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Ovarian Cancer Targeted Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Region (2019-2024)
Table 9. Global Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Region (2025-2030)
Table 11. Ovarian Cancer Targeted Therapy Drugs Market Trends
Table 12. Ovarian Cancer Targeted Therapy Drugs Market Drivers
Table 13. Ovarian Cancer Targeted Therapy Drugs Market Challenges
Table 14. Ovarian Cancer Targeted Therapy Drugs Market Restraints
Table 15. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Players (2019-2024)
Table 17. Global Top Ovarian Cancer Targeted Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ovarian Cancer Targeted Therapy Drugs as of 2023)
Table 18. Ranking of Global Top Ovarian Cancer Targeted Therapy Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Ovarian Cancer Targeted Therapy Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Ovarian Cancer Targeted Therapy Drugs, Headquarters and Area Served
Table 21. Global Key Players of Ovarian Cancer Targeted Therapy Drugs, Product and Application
Table 22. Global Key Players of Ovarian Cancer Targeted Therapy Drugs, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Ovarian Cancer Targeted Therapy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Merck KGaA Company Details
Table 48. Merck KGaA Business Overview
Table 49. Merck KGaA Ovarian Cancer Targeted Therapy Drugs Product
Table 50. Merck KGaA Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 51. Merck KGaA Recent Development
Table 52. GlaxoSmithKline plc Company Details
Table 53. GlaxoSmithKline plc Business Overview
Table 54. GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Product
Table 55. GlaxoSmithKline plc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 56. GlaxoSmithKline plc Recent Development
Table 57. Johnson & Johnson Services, Inc Company Details
Table 58. Johnson & Johnson Services, Inc Business Overview
Table 59. Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Product
Table 60. Johnson & Johnson Services, Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 61. Johnson & Johnson Services, Inc Recent Development
Table 62. F. Hoffmann-La Roche AG Company Details
Table 63. F. Hoffmann-La Roche AG Business Overview
Table 64. F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Product
Table 65. F. Hoffmann-La Roche AG Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 66. F. Hoffmann-La Roche AG Recent Development
Table 67. Boehringer Ingelheim International GmbH Company Details
Table 68. Boehringer Ingelheim International GmbH Business Overview
Table 69. Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Product
Table 70. Boehringer Ingelheim International GmbH Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 71. Boehringer Ingelheim International GmbH Recent Development
Table 72. Abbvie Inc Company Details
Table 73. Abbvie Inc Business Overview
Table 74. Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Product
Table 75. Abbvie Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 76. Abbvie Inc Recent Development
Table 77. AstraZeneca Company Details
Table 78. AstraZeneca Business Overview
Table 79. AstraZeneca Ovarian Cancer Targeted Therapy Drugs Product
Table 80. AstraZeneca Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 81. AstraZeneca Recent Development
Table 82. Pfizer, Inc Company Details
Table 83. Pfizer, Inc Business Overview
Table 84. Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Product
Table 85. Pfizer, Inc Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 86. Pfizer, Inc Recent Development
Table 87. Clovis Oncology Company Details
Table 88. Clovis Oncology Business Overview
Table 89. Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Product
Table 90. Clovis Oncology Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 91. Clovis Oncology Recent Development
Table 92. Amgen Inc. Company Details
Table 93. Amgen Inc. Business Overview
Table 94. Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Product
Table 95. Amgen Inc. Revenue in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024) & (US$ Million)
Table 96. Amgen Inc. Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report
List of Figures
Figure 1. Ovarian Cancer Targeted Therapy Drugs Picture
Figure 2. Global Ovarian Cancer Targeted Therapy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Type: 2023 VS 2030
Figure 4. PARP Inhibitors Features
Figure 5. Angiogenesis Inhibitors Features
Figure 6. Others Features
Figure 7. Global Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Drug Stores and Retail Pharmacy Case Studies
Figure 11. Online Providers Case Studies
Figure 12. Ovarian Cancer Targeted Therapy Drugs Report Years Considered
Figure 13. Global Ovarian Cancer Targeted Therapy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Ovarian Cancer Targeted Therapy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Ovarian Cancer Targeted Therapy Drugs Market Share by Players in 2023
Figure 17. Global Top Ovarian Cancer Targeted Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ovarian Cancer Targeted Therapy Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Ovarian Cancer Targeted Therapy Drugs Revenue in 2023
Figure 19. North America Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Ovarian Cancer Targeted Therapy Drugs Market Share by Country (2019-2030)
Figure 21. United States Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Ovarian Cancer Targeted Therapy Drugs Market Share by Country (2019-2030)
Figure 25. Germany Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Share by Region (2019-2030)
Figure 33. China Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Ovarian Cancer Targeted Therapy Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. UAE Ovarian Cancer Targeted Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Merck KGaA Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 49. GlaxoSmithKline plc Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 50. Johnson & Johnson Services, Inc Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 51. F. Hoffmann-La Roche AG Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 52. Boehringer Ingelheim International GmbH Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 53. Abbvie Inc Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 54. AstraZeneca Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 55. Pfizer, Inc Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 56. Clovis Oncology Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 57. Amgen Inc. Revenue Growth Rate in Ovarian Cancer Targeted Therapy Drugs Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
